

---

**CONFIRMATORY ASSIGNMENT**

---

WHEREAS, **CATALENT PHARMA SOLUTIONS, LLC**, a corporation of the state of Delaware, having its principal place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (hereinafter "ASSIGNOR"), by virtue of employing a named inventor has the ownership right to certain inventions and improvements disclosed in the following PCT Patent Application titled "**MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS**," filed in the United States Patent and Trademark Office acting as the Receiving Office on **September 6, 2019**, and assigned **PCT Application No. PCT/US19/50073** ("PCT Application"), which claims priority to U.S. provisional patent application titled "**MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS**," which is identified in the United States Patent and Trademark Office by Provisional Application No. **62/727,954** ("Priority Document"), filed on **September 6, 2018**, and for which an application for Letters Patent in the United States and other foreign jurisdictions claiming priority to the said PCT Application and Priority Document will be made.

WHEREAS, **ACHILLION PHARMACEUTICALS, INC.** ("ASSIGNEE"), a business entity organized and existing under the laws of the state of Delaware, and having its principal offices at 1777 Sentry Parkway West, VEVA Building #14, Suite 200, Blue Bell, Pennsylvania 19422, is entitled to the ownership of these inventions and the PCT Application and its Priority Document describing these inventions by virtue of a Master Development and Clinical Supply Agreement dated October 14, 2013, by and between ASSIGNEE and ASSIGNOR, and thus desires to confirm the ownership of the entire right, title, and interest in and to said inventions, improvements, know-how, PCT Application and its Priority Document, and in and to the Letters Patents which may be granted therefrom.

NOW, THEREFORE, for good and valuable consideration previously received, the receipt and sufficiency of which is hereby confirmed, ASSIGNOR hereby acknowledges and confirms the previous transfer of the full, exclusive, and entire right, title, and interest in and to said PCT Application and its Priority Document, and in and to all inventions and improvements disclosed and described in said PCT Application and its Priority Document;

For the same consideration, ASSIGNOR further confirms and acknowledges that it has sold, assigned, and transferred to ASSIGNEE the full, exclusive, and entire right, title, and interest in and to any U.S.

nonprovisional or foreign application or applications corresponding to said PCT Application and/or its Priority Document, in whole or in part, and to any Letters Patents and similar protective rights granted on said U.S. nonprovisional or foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said U.S. nonprovisional or foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations; said U.S. nonprovisional or foreign applications to be filed and issued in the name of ASSIGNEE, or its designee insofar as permitted by applicable law;


AND, for the same consideration, ASSIGNOR confirms its agreement to sign all lawful papers, execute all nonprovisional applications and other applications, make all assignments and rightful oaths, and generally do everything possible to aid ASSIGNEE, its successors, assigns, and nominees to obtain and enforce proper protection for all said inventions and improvements in all countries throughout the world.

The ASSIGNOR agrees that this assignment is effective from the 14th day of October 2013, and agrees and confirms that this assignment is fully effective for PCT/US19/50073 from the 6th day of September 2019, and its Priority Documents U.S. Provisional Application No. 62/727,954 from the 6th day of September 2018.

IN TESTIMONY, WHEREOF, the ASSIGNOR and ASSIGNEE set hereunto their hands and seal this date.

  
.....  
**Authorized Signatory**  
**Catalent Pharma Solutions, LLC**

Date: 10-1-19

  
.....  
**Authorized Signatory**  
**Achillion Pharmaceuticals, Inc.**

Date: January 8, 2020